These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31599492)

  • 41. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
    Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rare
    Panagopoulos I; Andersen K; Eilert-Olsen M; Rognlien AG; Munthe-Kaas MC; Micci F; Heim S
    Cancer Genomics Proteomics; 2021; 18(2):121-131. PubMed ID: 33608309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
    Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
    Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
    [No Abstract]   [Full Text] [Related]  

  • 44. B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Kemps PG; Cleven AHG; van Wezel T; van Eijk R; Bot FJ; Veelken H; van Balen P; Kerkhoffs JH
    Am J Hematol; 2020 Nov; 95(11):1427-1429. PubMed ID: 32243611
    [No Abstract]   [Full Text] [Related]  

  • 45. The role of constitutive activation of FMS-related tyrosine kinase-3 and
    Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
    Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
    [No Abstract]   [Full Text] [Related]  

  • 46. Dysplastic features seen in a patient with acute myeloid leukemia harboring the KTM2A-TET1 fusion gene.
    Kawai H; Matsushita H; Aoyama Y; Matsui K; Onizuka M; Ando K
    Int J Hematol; 2018 Jul; 108(1):1-2. PubMed ID: 29744807
    [No Abstract]   [Full Text] [Related]  

  • 47. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
    Xie W; Tang G; Wang E; Kim Y; Cloe A; Shen Q; Zhou Y; Garcia-Manero G; Loghavi S; Hu AY; Wang S; Bueso-Ramos CE; Kantarjian HM; Medeiros LJ; Hu S
    Ann Hematol; 2020 Mar; 99(3):487-500. PubMed ID: 32006151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
    Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
    Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.
    Matlawska-Wasowska K; Kang H; Devidas M; Wen J; Harvey RC; Nickl CK; Ness SA; Rusch M; Li Y; Onozawa M; Martinez C; Wood BL; Asselin BL; Chen IM; Roberts KG; Baruchel A; Soulier J; Dombret H; Zhang J; Larson RS; Raetz EA; Carroll WL; Winick NJ; Aplan PD; Loh ML; Mullighan CG; Hunger SP; Heerema NA; Carroll AJ; Dunsmore KP; Winter SS
    Leukemia; 2016 Sep; 30(9):1909-12. PubMed ID: 26952838
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
    Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
    Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment.
    Jung R; Jacobs U; Krumbholz M; Langer T; Keller T; De Lorenzo P; Valsecchi MG; van der Velden VH; Moericke A; Stanulla M; Teigler-Schlegel A; Panzer-Gruemayer ER; van Dongen JJ; Schrappe M; den Boer ML; Pieters R; Rascher W; Metzler M
    Leukemia; 2010 Apr; 24(4):903-7. PubMed ID: 20164851
    [No Abstract]   [Full Text] [Related]  

  • 52. The MLL recombinome of acute leukemias in 2017.
    Meyer C; Burmeister T; Gröger D; Tsaur G; Fechina L; Renneville A; Sutton R; Venn NC; Emerenciano M; Pombo-de-Oliveira MS; Barbieri Blunck C; Almeida Lopes B; Zuna J; Trka J; Ballerini P; Lapillonne H; De Braekeleer M; Cazzaniga G; Corral Abascal L; van der Velden VHJ; Delabesse E; Park TS; Oh SH; Silva MLM; Lund-Aho T; Juvonen V; Moore AS; Heidenreich O; Vormoor J; Zerkalenkova E; Olshanskaya Y; Bueno C; Menendez P; Teigler-Schlegel A; Zur Stadt U; Lentes J; Göhring G; Kustanovich A; Aleinikova O; Schäfer BW; Kubetzko S; Madsen HO; Gruhn B; Duarte X; Gameiro P; Lippert E; Bidet A; Cayuela JM; Clappier E; Alonso CN; Zwaan CM; van den Heuvel-Eibrink MM; Izraeli S; Trakhtenbrot L; Archer P; Hancock J; Möricke A; Alten J; Schrappe M; Stanulla M; Strehl S; Attarbaschi A; Dworzak M; Haas OA; Panzer-Grümayer R; Sedék L; Szczepański T; Caye A; Suarez L; Cavé H; Marschalek R
    Leukemia; 2018 Feb; 32(2):273-284. PubMed ID: 28701730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
    Matthijssens F; Sharma ND; Nysus M; Nickl CK; Kang H; Perez DR; Lintermans B; Van Loocke W; Roels J; Peirs S; Demoen L; Pieters T; Reunes L; Lammens T; De Moerloose B; Van Nieuwerburgh F; Deforce DL; Cheung LC; Kotecha RS; Risseeuw MD; Van Calenbergh S; Takarada T; Yoneda Y; van Delft FW; Lock RB; Merkley SD; Chigaev A; Sklar LA; Mullighan CG; Loh ML; Winter SS; Hunger SP; Goossens S; Castillo EF; Ornatowski W; Van Vlierberghe P; Matlawska-Wasowska K
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33555272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23).
    Nemoto N; Suzukawa K; Shimizu S; Shinagawa A; Takei N; Taki T; Hayashi Y; Kojima H; Kawakami Y; Nagasawa T
    Genes Chromosomes Cancer; 2007 Sep; 46(9):813-9. PubMed ID: 17551948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
    Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
    Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].
    Nasedkina TV; Ikonnikova AY; Tsaur GA; Karateeva AV; Ammour YI; Avdonina MA; Karachunskii AI; Zasedatelev AS
    Mol Biol (Mosk); 2016; 50(6):968-977. PubMed ID: 28064313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
    Stubbs MC; Krivtsov AV
    Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.
    Felix CA; Slater DJ; Davenport JW; Yu X; Gregory BD; Li MM; Rappaport EF; Cheung NV
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29344. PubMed ID: 34550633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Congenital acute myeloid leukaemia with KMT2A rearrangement.
    Wan Ariffin E; Jones H; Bhatnagar N
    Br J Haematol; 2018 Jul; 182(2):169. PubMed ID: 29797490
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.